ICIs such as nivolumab and pembrolizumab, which target PD-1, and ipilimumab, targeting CTLA-4, have dramatically improved survival rates for patients with advanced NSCLC (309). The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.